Status:

COMPLETED

Biopsies and Polyps

Lead Sponsor:

Laval University

Conditions:

Nasal Polyps

Asthma

Eligibility:

All Genders

18-65 years

Brief Summary

Background: Nasal polyps are found in about 5% of asthmatic patients.A close link exists between the upper and lower airways and the concept of the "United Airways" has emerged mainly from studies on ...

Detailed Description

The study will include 2 visits separated by a maximum of 7 days. During the first visit, subjects' characteristics will be documented by a locally validated questionnaire. Allergy skin prick tests, s...

Eligibility Criteria

Inclusion

  • For all subjects:
  • Non smoking men or women aged 18 to 65 years old.
  • Subjects will have nasal polyps as defined above.
  • For asthmatic subjects:
  • Subjects will have a history consistent with asthma according to the criteria of the ATS\[18\] defined on the basis of episodic or persistent chest tightness, wheeze or cough in the past 6 months. At entry into the study, FEV1 will be over 70% predicted.
  • Asthma will have been stable for at least 3 months before entering the trial.
  • Asthma medication will have been stable for at least 1 month prior to the study.
  • For non asthmatic subjects:
  • A methacholine challenge test with a PC20 (provoking concentration of methacholine to cause a 20% fall in FEV1) over 16 mg/mL.

Exclusion

  • For all subjects:
  • Smoking (current smoking) or ex-smoking (les than 6 months or history of more than 10 pack-year of smoking).
  • Use of anti-leukotriene medication within the last 3 months.
  • Use of systemic corticosteroids within the last 3 months.
  • Use of anti-coagulant therapy.
  • Recent (less than 1 month) upper or lower respiratory tract infection, any other condition that may interfere with the evaluations.
  • Pregnancy, breast-feeding or planned pregnancy during the study. Fertile woman not using acceptable contraceptive measures, as judged by the investigator.
  • Subjects unable to perform or with contraindications to the tests proposed.
  • Subjects who are, in the opinion of the investigator, mentally or legally incapacitated thus preventing informed consent from being obtained.
  • For asthmatic subjects:
  • Unstable asthma shown by respiratory symptoms and B2-agonists need more than 3 times/week and nocturnal asthma symptoms.

Key Trial Info

Start Date :

July 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2009

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT00835445

Start Date

July 1 2007

End Date

September 1 2009

Last Update

January 7 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hopital Laval

Ste-Foy, Quebec, Canada, G1V 4G5